Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
Karl BordeauMorgan MichaletAïcha KeskesSimon ValdenairePierre DebuireMarie CantaloubeMorgane CabailléFabienne PortalesRoxana DraghiciMarc YchouEric AssenatThibault MazardEmmanuelle SamalinLudovic GauthierPierre-Emmanuel ColomboSebastien CarrereFrançois-Régis SoucheNorbert AillèresPascal FenogliettoDavid AzriaOlivier RiouPublished in: Cancers (2022)
To our knowledge, this is the largest series of SMART for pancreatic tumors. The treatment was well tolerated with only low-grade toxicities. Long-term OS and LC rates were achieved. SMART achieved high secondary resection rates in LAPC patients.
Keyphrases
- low grade
- end stage renal disease
- high grade
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- early stage
- magnetic resonance
- peritoneal dialysis
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- mass spectrometry
- patient reported outcomes
- rectal cancer
- contrast enhanced
- combination therapy
- patient reported